https://www.nasdaq.com/press-release/the-lancet-diabetes-endocrinology-publishes-positive-results-for-the-mpowered-phase-3
https://www.nasdaq.com/press-release/the-lancet-diabetes-endocrinology-publishes-positive-results-for-the-mpowered-phase-0
https://www.nasdaq.com/press-release/total-voting-rights-2022-01-04
https://www.nasdaq.com/press-release/total-voting-rights-2021-12-01
https://www.nasdaq.com/press-release/director-pdmr-shareholding-2021-11-30
https://www.nasdaq.com/press-release/amryt-provides-update-on-regulatory-review-process-for-oleogel-s10-2021-11-23
https://www.nasdaq.com/press-release/amryt-provides-update-on-regulatory-review-process-for-oleogel-s10-2021-11-23-0
https://www.nasdaq.com/press-release/amryt-announces-the-cancellation-of-admission-of-its-ordinary-shares-to-trading-on
https://www.nasdaq.com/press-release/amryt-announces-the-cancellation-of-admission-of-its-ordinary-shares-to-trading-on-0
https://www.nasdaq.com/press-release/amryt-reports-strong-q3-2021-results-2021-11-03
https://www.nasdaq.com/press-release/total-voting-rights-2021-11-01
https://www.nasdaq.com/press-release/amryt-to-report-q3-2021-results-and-host-conference-call-webcast-on-november-3-2021
https://www.nasdaq.com/press-release/amryt-announces-new-patents-for-oleogel-s10-and-mycapssar-2021-10-19
https://www.nasdaq.com/press-release/total-voting-rights-2021-10-01
https://www.nasdaq.com/press-release/amryt-raises-full-year-2021-revenue-guidance-to-%24220m-%24225m-2021-09-13
https://www.nasdaq.com/press-release/total-voting-rights-2021-09-01
https://www.nasdaq.com/press-release/amryt-issues-ordinary-shares-and-total-voting-rights-2021-08-19
https://www.nasdaq.com/press-release/director-pdmr-shareholding-2021-08-10
https://www.nasdaq.com/press-release/amryt-virtual-capital-markets-event-september-13-2021-1000-1200-edt-2021-08-09
https://www.nasdaq.com/press-release/amryt-reports-record-q2-2021-results-and-raises-fy-2021-guidance-2021-08-06
https://www.nasdaq.com/press-release/amryt-successfully-completes-acquisition-of-chiasma-inc.-board-appointments-issues
https://www.nasdaq.com/press-release/result-of-general-meetings-2021-07-28
https://www.nasdaq.com/press-release/amryt-to-report-q2-2021-results-and-host-conference-call-webcast-on-august-6-2021-07
https://www.nasdaq.com/press-release/publication-of-circular-to-amryt-shareholders-in-relation-to-the-acquisition-of
https://www.nasdaq.com/press-release/publication-of-circular-to-amryt-shareholders-in-relation-to-the-acquisition-of-0
https://www.nasdaq.com/press-release/amryt-pharma-announces-filing-of-preliminary-registration-statement-on-form-f-4-in-0
https://www.nasdaq.com/press-release/amryt-pharma-announces-filing-of-preliminary-registration-statement-on-form-f-4-in
https://www.nasdaq.com/press-release/fda-confirms-nda-for-oleogel-s10-will-not-require-an-advisory-committee-meeting-0
https://www.nasdaq.com/press-release/fda-confirms-nda-for-oleogel-s10-will-not-require-an-advisory-committee-meeting-2021
https://www.nasdaq.com/press-release/fda-grants-priority-review-for-new-drug-application-for-oleogel-s10-for-the-treatment
https://www.nasdaq.com/press-release/fda-grants-priority-review-for-new-drug-application-for-oleogel-s10-for-the-0
https://www.nasdaq.com/press-release/amryt-announces-fda-acceptance-of-new-drug-application-for-oleogel-s10-for-the
https://www.nasdaq.com/press-release/amryt-announces-fda-acceptance-of-new-drug-application-for-oleogel-s10-for-the-0
https://www.nasdaq.com/press-release/amryt-reports-record-q1-2021-financial-and-operating-results-2021-05-05
https://www.nasdaq.com/press-release/amryt-reports-record-q1-2021-financial-and-operating-results-2021-05-05-0
https://www.nasdaq.com/press-release/amryt-pharma-to-acquire-chiasma-inc.-to-further-strengthen-global-leadership-in-rare
https://www.nasdaq.com/press-release/amryt-pharma-to-acquire-chiasma-inc.-to-further-strengthen-global-leadership-in-1
https://www.nasdaq.com/press-release/amryt-to-report-q1-2021-results-and-host-conference-call-webcast-on-may-5-2021-04-15
https://www.nasdaq.com/press-release/amryt-announces-the-appointment-of-sheila-frame-as-president-americas-2021-04-06
https://www.nasdaq.com/press-release/amryt-submits-a-new-drug-application-to-the-us-food-and-drug-administration-for
https://www.nasdaq.com/press-release/amryt-announces-results-from-an-investigator-sponsored-study-of-lomitapide-in-fcs
https://www.nasdaq.com/press-release/amryt-announces-validation-of-its-maa-by-the-ema-for-oleogel-s10-filsuvezr-2021-03-29
https://www.nasdaq.com/press-release/amryt-receives-positive-feedback-from-the-fda-on-the-path-forward-for-myaleptr
https://www.nasdaq.com/press-release/amryt-receives-reimbursement-approval-from-the-french-ministry-of-social-affairs-and
https://www.nasdaq.com/press-release/exercise-of-options-and-total-voting-rights-2021-03-12
https://www.nasdaq.com/press-release/exercise-of-warrants-issue-of-ordinary-shares-and-total-voting-rights-2021-03-11
https://www.nasdaq.com/press-release/director-pdmr-shareholding-2021-03-08
https://www.nasdaq.com/press-release/amryt-and-medison-pharma-sign-distribution-agreement-for-myaleptar-metreleptin-in
https://www.nasdaq.com/press-release/amryt-to-announce-q4-and-fy-2020-results-on-thursday-march-4-2021-2021-02-24
https://www.nasdaq.com/press-release/amryt-and-medison-pharma-sign-multi-regional-distribution-agreements-in-canada-and
https://www.nasdaq.com/press-release/amryt-and-medison-pharma-sign-multi-regional-distribution-agreements-in-canada-and-0
https://www.nasdaq.com/press-release/amryt-receives-reimbursement-approval-from-nice-for-myaleptar-metreleptin-in-0
https://www.nasdaq.com/press-release/amryt-receives-reimbursement-approval-from-nice-for-myaleptar-metreleptin-in-england
https://www.nasdaq.com/press-release/amryt-granted-orphan-drug-designation-by-the-fda-for-ap103-2020-12-23
https://www.nasdaq.com/press-release/amryt-receives-ministry-of-health-reimbursement-approval-for-lojuxtar-lomitapide-in
https://www.nasdaq.com/press-release/holdings-in-company-2020-12-09
https://www.nasdaq.com/press-release/holdings-in-company-2020-12-09-0
https://www.nasdaq.com/press-release/amryt-group-receives-marketing-authorisation-approval-for-lojuxtar-in-brazil-2020-0
https://www.nasdaq.com/press-release/amryt-group-receives-marketing-authorisation-approval-for-lojuxtar-in-brazil-2020-12
https://www.nasdaq.com/press-release/amryt-announces-%2440m-private-placement-with-leading-biotech-investors-2020-12-08-0
https://www.nasdaq.com/press-release/amryt-announces-%2440m-private-placement-with-leading-biotech-investors-2020-12-08
https://www.nasdaq.com/press-release/amryt-reports-record-q3-2020-results-raising-fy-2020-revenue-guidance-2020-11-05-0
https://www.nasdaq.com/press-release/amryt-reports-record-q3-2020-results-raising-fy-2020-revenue-guidance-2020-11-05
https://www.nasdaq.com/press-release/amryt-announces-positive-results-from-phase-3-trial-of-filsuvezr-in-epidermolysis
https://www.nasdaq.com/press-release/amryt-announces-positive-results-from-phase-3-trial-of-filsuvezr-in-epidermolysis-0
https://www.nasdaq.com/press-release/amryt-and-swixx-sign-distribution-deal-for-lojuxta-2020-10-19-0
https://www.nasdaq.com/press-release/amryt-and-swixx-sign-distribution-deal-for-lojuxta-2020-10-19
https://www.nasdaq.com/press-release/notice-of-results-2020-10-14
https://www.nasdaq.com/press-release/notice-of-results-2020-10-14-0
https://www.nasdaq.com/press-release/holdings-in-company-2020-10-12
https://www.nasdaq.com/press-release/virtual-analyst-investor-event-tuesday-november-3-2020-2020-10-09
https://www.nasdaq.com/press-release/amryt-to-present-ease-trial-data-by-late-breaking-presentation-at-eadv-on-october-31
https://www.nasdaq.com/press-release/exercise-of-options-and-total-voting-rights-2020-10-01
https://www.nasdaq.com/press-release/holdings-in-company-2020-09-30
https://www.nasdaq.com/press-release/amryt-supports-global-fh-awareness-day-september-24-2020-2020-09-23
https://www.nasdaq.com/press-release/exercise-of-warrants-issue-of-ordinary-shares-and-total-voting-rights-2020-09-21-0
https://www.nasdaq.com/press-release/exercise-of-warrants-issue-of-ordinary-shares-and-total-voting-rights-2020-09-21
https://www.nasdaq.com/press-release/amryt-receives-positive-opinion-from-ema-on-orphan-drug-designation-for-ap103-2020-09
https://www.nasdaq.com/press-release/positive-top-line-results-from-phase-3-trial-in-eb-2020-09-09
https://www.nasdaq.com/press-release/amryt-pharma-notification-of-cancellation-of-admission-to-euronext-growth-2020-08-11
